Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Humacyte, Inc. (HUMA) vs Molecular Partners AG Sponsored ADR (MOLN)

Humacyte, Inc. and Molecular Partners AG Sponsored ADR are both Biotechnology companies. Humacyte, Inc. and Molecular Partners AG Sponsored ADR are of similar size ($166.7M and $160.5M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against −28.0%. Molecular Partners AG Sponsored ADR has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 17 metrics below, Molecular Partners AG Sponsored ADR leads on 14 and Humacyte, Inc. on 3.

Valuation

Metric HUMA MOLN Biotechnology median
P/E n/m n/m 7.88
P/S 61.83 28.96 11.47
P/B 4.20 2.21 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 55.84 13.74 10.73
Earnings yield (87.50%) (40.52%) (28.84%)
Free cash flow yield (74.39%) (35.09%) (23.03%)

Profitability

Metric HUMA MOLN Biotechnology median
Gross margin (494.58%) 0.00% 65.16%
Operating margin (5,240.78%) 0.00% 0.00%
Net margin (4,448.89%) 0.00% 0.00%
Free cash flow margin (4,599.72%) 0.00% 0.00%
Return on equity (534.42%) (63.89%) (57.72%)
Return on assets (68.16%) (52.73%) (49.22%)
Return on invested capital (433.66%) 0.00% 0.00%

Growth

Metric HUMA MOLN Biotechnology median
Revenue growth (TTM) 149.82% (27.99%) 5.64%
EPS growth (last fiscal year) 79.37% (9.94%) —
Revenue growth, 5-year CAGR — (23.12%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HUMA MOLN Biotechnology median
Debt to equity 2.07 0.00 0.00
Current ratio 6.21 7.27 4.73
Net debt to EBITDA (0.12) 1.66 0.96

Dividend

Metric HUMA MOLN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HUMA MOLN Biotechnology median
Market cap 166.65m 160.52m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack